Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults with Gorlin Syndrome
- Conditions
- Interventions
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Sol-Gel Technologies, Ltd.
- Target Recruit Count
- 140
- Registration Number
- NCT06050122
- Locations
- 🇺🇸
Northwest Arkansas Clinical Trials Center, Rogers, Arkansas, United States
🇺🇸Center for Dermatology Clinical Research, Fremont, California, United States
🇺🇸University of California Los Angeles (UCLA) - Center for Inflammatory Bowel Diseases - Westwood Location, Los Angeles, California, United States
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties
- Conditions
- Interventions
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Sol-Gel Technologies, Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT05675501
- Locations
- 🇺🇸
Integrative Skin Science and Research (ISSR), Sacramento, California, United States
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
- First Posted Date
- 2020-03-16
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Sol-Gel Technologies, Ltd.
- Target Recruit Count
- 107
- Registration Number
- NCT04308395
- Locations
- 🇺🇸
Laser & Skin Surgery Center of Indiana, Indianapolis, Indiana, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC
- Conditions
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Sol-Gel Technologies, Ltd.
- Target Recruit Count
- 47
- Registration Number
- NCT04155190
- Locations
- 🇺🇸
The Dermatology Center of Newport, Newport Beach, California, United States
🇺🇸Axiom Research, LLC, Colton, California, United States
🇺🇸Center for Dermatology Clinical Research, Inc., Fremont, California, United States
MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3
- First Posted Date
- 2019-08-16
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Sol-Gel Technologies, Ltd.
- Target Recruit Count
- 62
- Registration Number
- NCT04059523
- Locations
- 🇺🇸
DermResearch, Inc., Austin, Texas, United States
🇺🇸J&S Studies, Inc, College Station, Texas, United States
A Study of S6G5T-3 in the Treatment of Acne Vulgaris
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Sol-Gel Technologies, Ltd.
- Target Recruit Count
- 424
- Registration Number
- NCT03761784
- Locations
- 🇺🇸
Dermatology Consulting Services, High Point, North Carolina, United States
A Study of S6G5T3 in the Treatment of Acne Vulgaris
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Sol-Gel Technologies, Ltd.
- Target Recruit Count
- 434
- Registration Number
- NCT03761810
- Locations
- 🇺🇸
Sol-Gel site 501, Tampa, Florida, United States
Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (5-FU) Cream
- Conditions
- Interventions
- First Posted Date
- 2018-11-01
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Sol-Gel Technologies, Ltd.
- Target Recruit Count
- 462
- Registration Number
- NCT03727074
- Locations
- 🇺🇸
Core Healthcare Group, Cerritos, California, United States
Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)
- Conditions
- Interventions
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Sol-Gel Technologies, Ltd.
- Target Recruit Count
- 174
- Registration Number
- NCT03703310
- Locations
- 🇮🇹
Ospedale Vanvitelli-University della Campania-Dermatologia Edificio 9, Napoli, Italy
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇫🇷CHRU de Lille - Hopital Claude HURIEZ, Lille Cedex, France
A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- Sol-Gel Technologies, Ltd.
- Target Recruit Count
- 547
- Registration Number
- NCT03564145
- Locations
- 🇺🇸
Sol-Gel, Rochester, New York, United States